ADHD Medication and Your Heart: Blood Pressure, Heart Rate and Screening

Stimulants, and the non-stimulants atomoxetine and viloxazine, raise blood pressure and heart rate slightly on average; guanfacine lowers them. FDA labeling for stimulants describes average increases of about 2 to 4 mm Hg in blood pressure and 3 to 6 beats per minute in heart rate, with larger increases in some patients. For most healthy children and adults that change is small, but it is the reason every prescriber should check your heart history before starting and keep measuring blood pressure and pulse afterward.

Large studies have not shown a clear increase in heart attack, stroke or sudden death with current use of ADHD medication in young and middle-aged people, but a 2024 Swedish study linked longer cumulative use with a higher risk of cardiovascular disease, mainly high blood pressure. The sensible response is not alarm. It is good screening at the start and consistent monitoring for as long as you take the medication.

What ADHD medications do to blood pressure and heart rate

Stimulants (amphetamine and methylphenidate products) act on the nervous system in ways that also nudge the cardiovascular system. Their labels say to monitor all patients for possible fast heart rate and high blood pressure. Non-stimulants are not exempt. Atomoxetine (Strattera) and viloxazine (Qelbree) labels both call for heart rate and blood pressure checks before treatment, after dose increases and periodically during treatment. Guanfacine extended-release (Intuniv) works in the opposite direction: its label warns about low blood pressure, slow heart rate and fainting.

A 2025 network meta-analysis in The Lancet Psychiatry pooled 102 randomized trials, mostly lasting several weeks. It found that amphetamines, atomoxetine, lisdexamfetamine, methylphenidate and viloxazine all raised blood pressure, pulse or both; stimulants did not raise these values more than atomoxetine or viloxazine; and guanfacine lowered them. The authors concluded that blood pressure and pulse should be monitored with any ADHD medication, not only stimulants, and noted that almost no trials lasted long enough to show long-term effects.

The differences between classes are covered in stimulant vs non-stimulant medication and Qelbree vs Strattera.

What the long-term studies show, and what they don't

The evidence has two layers, and they point in slightly different directions.

Serious events in the short to medium term

A US cohort of about 1.2 million children and young adults aged 2 to 24 found no increased risk of sudden cardiac death, heart attack or stroke among current users of ADHD drugs; the authors noted that a doubling of risk could not be ruled out, but that the absolute risk would still be low. A companion study of adults aged 25 to 64 likewise found no increased risk of these serious events with current or new use. A 2022 meta-analysis of 19 observational studies found no statistically significant association between ADHD medication and cardiovascular disease across age groups, while noting that a modest increase could not be ruled out, especially for cardiac arrest and fast heart rhythms.

Cumulative use over years

The 2024 JAMA Psychiatry study used Swedish national registers covering 278,027 people aged 6 to 64 with ADHD. Compared with no use, longer cumulative use of ADHD medication was associated with higher odds of cardiovascular disease; each additional year of use was associated with about a 4% higher risk, with the steepest rise in the first 3 years. The clearest links were with high blood pressure and arterial disease, and the pattern was similar in people under and over 25.

How to read these numbers

• These are observational studies. They show associations, not proof that the medication caused the disease.
• A 4% increase per year is a relative figure. Your actual risk depends on your starting risk: age, family history, weight, smoking, blood pressure and other conditions.
• The finding that matters most for daily life is high blood pressure, which is easy to measure and treat.
• The same study's authors recommended weighing benefits and risks carefully and monitoring cardiovascular signs and symptoms regularly throughout treatment.

Untreated ADHD has its own costs, and nothing here means you should stop a medication that is helping. If you are worried, raise it at your next visit and ask whether your own numbers justify any change.

Screening before the first prescription

The FDA labels set the minimum. Before starting a stimulant, the prescriber should take a careful personal history, a family history of sudden death or ventricular arrhythmia, and do a physical exam. The label says to avoid stimulants in people with known structural heart abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease or other serious heart disease.

The UK's NICE guideline on ADHD (NG87) gives a more detailed checklist. Before medication, it calls for a medical history, a list of current medicines, height and weight, baseline pulse and blood pressure measured with an appropriately sized cuff, and a cardiovascular assessment. It recommends a cardiology opinion before starting if any of the following apply:

• congenital heart disease or previous heart surgery
• sudden death in a first-degree relative under 40 suggesting heart disease
• shortness of breath on exertion compared with peers
• fainting on exertion or in response to fright or noise
• palpitations that are rapid, regular and start and stop suddenly
• chest pain suggesting a cardiac cause
• signs of heart failure or a heart murmur
• blood pressure in the hypertensive range for adults

For children and teens, NICE recommends referral to a pediatric hypertension specialist first if blood pressure is consistently above the 95th centile for age and height. NICE is a UK body, so US practice may differ in details, but its criteria are a clear, published version of what a careful prescriber asks.

Before your first medication visit, gather what the prescriber needs. How to prepare your medication history includes a template; add any heart tests you have had and the results of recent blood pressure checks.

When is an ECG needed?

An ECG (electrocardiogram) is not part of routine screening for most people. NICE says an ECG is not needed before starting stimulants, atomoxetine or guanfacine unless one of the warning features above is present, or the person takes another medicine for a coexisting condition that may raise cardiac risk. It also advises against routine ECGs during treatment unless there is a clinical reason.

In the United States, the American Heart Association published a scientific statement in 2008 on cardiovascular monitoring of children and adolescents with heart disease who take ADHD medication. Situations in which a prescriber or primary care doctor may order an ECG or ask a cardiologist, several of which overlap with the NICE criteria above, include:

• a known heart condition, past heart surgery, or a pacemaker or implanted defibrillator
• a family history of sudden unexplained death, inherited arrhythmia or cardiomyopathy at a young age
• fainting during exercise, or palpitations with lightheadedness
• other medicines that affect heart rhythm
• abnormal findings on examination

If you fall into one of these groups, a cardiology opinion before starting does not rule medication out. It tells the prescriber which options are reasonable and how closely to monitor.

What monitoring looks like once you start

NICE recommends checking heart rate and blood pressure, compared with the normal range for age, before and after each dose change and every 6 months. If someone has a sustained resting heart rate above 120, an arrhythmia, or systolic blood pressure above the 95th percentile (or a clinically significant rise) on two occasions, NICE advises reducing the dose and referring to a specialist. For guanfacine, sustained low blood pressure on standing or fainting calls for a lower dose or a different medication.

Home blood pressure readings help, especially with telehealth

If your visits are by video, a home monitor with an upper-arm cuff lets your prescriber see real numbers. MedlinePlus advises resting at least 5 minutes first, sitting with your back supported and your arm at heart level, avoiding caffeine, tobacco or a meal in the previous 30 minutes, and asking your provider to compare your home readings with office readings to make sure the monitor is accurate. Take readings at roughly the same times and note when you took your dose; a reading taken a few hours after a stimulant dose tells a different story from one taken before it. Send a short log rather than a single number. Ongoing medication management explains how those check-ins usually work.

Symptoms that need attention

Stimulant labels tell patients to contact a health care provider right away for exertional chest pain, unexplained fainting or other symptoms that suggest heart disease. In practice:

• Chest pain, fainting, or a racing heartbeat with shortness of breath or lightheadedness: seek emergency care.
• Pounding or racing heartbeat at rest that does not settle, or new shortness of breath with exercise: contact your prescriber the same day.
• Higher readings on your home monitor than before, without symptoms: report them at or before your next visit.
• Dizziness on standing or feeling faint on guanfacine: contact your prescriber, and do not stop it suddenly without advice, because abrupt discontinuation can cause rebound high blood pressure.

Two of the non-stimulants carry boxed warnings about suicidal thoughts: atomoxetine in children and teenagers, and viloxazine in patients with ADHD treated in clinical studies. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Special situations

Adults with high blood pressure or other heart risk factors

High blood pressure is not listed as a contraindication on stimulant labels, but NICE recommends a cardiology opinion before starting medication if an adult's blood pressure is in the hypertensive range, and any high blood pressure changes the conversation. Your prescriber may want your blood pressure well controlled first, may favor a lower dose or a different class, and will usually want your primary care doctor involved. How your psychiatrist and primary care doctor should work together covers that coordination.

Children and teenagers

A child's blood pressure is judged against the normal range for age and height, so readings are compared with percentile charts rather than adult cutoffs. Ask whoever prescribes for your child how blood pressure, pulse, height and weight will be tracked. Child psychiatrist vs pediatrician for ADHD discusses who usually does this.

Caffeine, decongestants and other stimulating substances

Coffee, energy drinks, some cold medicines and some supplements can add to the effect on heart rate and blood pressure. List everything you take, including over-the-counter products, at each visit.

Questions to ask your prescriber

• Does anything in my history or family history call for an ECG or a cardiology opinion before I start?
• What blood pressure and heart rate would make you change the dose or the medication?
• How often will you check these, and do you want home readings?
• If my blood pressure rises, would you lower the dose, switch class, or add treatment, and who would manage it?
• Over years of treatment, how will we review whether the benefit still outweighs the cardiovascular risk for me?

If a shortage forces a change of product, the same monitoring applies to the new medication; see what to do if your pharmacy is out.

How the practice approaches it

The practice's ADHD assessment covers children and adults, in person or by telehealth, and ends with a written summary and treatment plan; plans may include lifestyle changes, nutrition, psychotherapy, executive-function coaching and medication when appropriate. Its prescribers include psychiatrists and psychiatric nurse practitioners. The practice has written about the overlap between psychiatric care and heart health in why your psychiatrist should care about your heart and about dosing philosophy in low-dose ADHD medication. More on how care begins is in the guide to choosing psychiatric care.

Frequently asked questions

Do I need an EKG before starting Adderall or Vyvanse?

Not routinely, if you have no heart symptoms, no known heart disease and no family history of sudden early death or inherited heart rhythm problems. Your prescriber will ask about these and may order an ECG or a cardiology opinion if any apply.

How much do stimulants raise blood pressure?

On average, FDA labeling describes increases of about 2 to 4 mm Hg in blood pressure and 3 to 6 beats per minute in heart rate. Some people have larger increases, which is why readings are checked after each dose change.

Is a non-stimulant safer for my heart?

Not necessarily. Atomoxetine and viloxazine also raise heart rate and blood pressure, by amounts similar to stimulants in short-term trials. Guanfacine lowers them and can cause dizziness or fainting. The best choice depends on your history.

Can I take ADHD medication if I already take blood pressure medicine?

Often yes, with closer monitoring and coordination with the doctor who treats your blood pressure. Your prescriber will want to know your recent readings and every medicine you take.

Does long-term ADHD medication cause heart disease?

Studies disagree in detail. Large US cohorts found no increase in heart attack, stroke or sudden death with current use, while a Swedish study linked years of cumulative use with more high blood pressure and arterial disease. These are associations, so regular monitoring is the practical answer.

Should I stop my medication if my blood pressure is high on a home reading?

No, not on your own. Recheck after resting, write the readings down and contact your prescriber. Seek emergency care if you also have chest pain, fainting, severe headache or shortness of breath.

Sources

1. Vyvanse (lisdexamfetamine dimesylate) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
2. Concerta (methylphenidate HCl) extended-release tablets prescribing information. Janssen / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
3. Strattera (atomoxetine) prescribing information. Eli Lilly / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
4. Qelbree (viloxazine extended-release capsules) prescribing information. Supernus Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
5. Intuniv (guanfacine extended-release) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
6. Attention deficit hyperactivity disorder: diagnosis and management (NG87), Recommendations. National Institute for Health and Care Excellence (NICE), 2018 (updated 2019). nice.org.uk
7. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Farhat LC et al., Lancet Psychiatry 12(5) (PMID 40203844), 2025. pubmed.ncbi.nlm.nih.gov
8. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. Zhang L et al., JAMA Psychiatry 81(2):178-187 (PMID 37991787), 2024. pubmed.ncbi.nlm.nih.gov
9. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. Zhang L et al., JAMA Network Open 5(11):e2243597 (PMID 36416824), 2022. pubmed.ncbi.nlm.nih.gov
10. ADHD drugs and serious cardiovascular events in children and young adults. Cooper WO et al., New England Journal of Medicine 365:1896-1904 (PMID 22043968), 2011. pubmed.ncbi.nlm.nih.gov
11. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. Habel LA et al., JAMA 306(24):2673-2683 (PMID 22161946), 2011. pubmed.ncbi.nlm.nih.gov
12. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association. Vetter VL et al., Circulation 117(18):2407-2423 (PMID 18427125), 2008. pubmed.ncbi.nlm.nih.gov
13. Blood pressure measurement. MedlinePlus Medical Encyclopedia, U.S. National Library of Medicine, 2026. medlineplus.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.